On Oct. 1, 2021, Humanigen announced it had submitted all the planned modules as well as a risk management plan and pediatric investigation plan for the lenzilumab Conditional Marketing Authorization (CMA) in hospitalized COVID-19 patients to the UKﾒs Medicines and Healthcare Products Regulatory Agency (MHRA)

MHRA has previously accepted the application for expedited COVID-19 rolling review.